NETIDINE D TAB
— Product

NETIDINE D TAB

RANITIDINE + DOMPERIDONE

NETIDINE D TAB is a tablet combining ranitidine with domperidone, pairing acid suppression with a prokinetic. It is used for gastro-oesophageal reflux, acid dyspepsia and reflux accompanied by nausea, bloating or a sensation of fullness.

01

Benefits

  • Ranitidine reduces gastric acid secretion, relieving heartburn and acid symptoms.
  • Domperidone increases gastric emptying and lower oesophageal sphincter tone, reducing the reflux itself.
  • The prokinetic action relieves nausea, bloating and early fullness that acid suppression alone does not address.
  • Particularly useful in reflux associated with delayed gastric emptying.
  • Faster symptomatic onset than a proton pump inhibitor.
02

Side effects

Not everyone gets these. Most are mild and settle as the course finishes.

Common
  • Headache
  • Dry mouth
  • Diarrhoea or constipation
  • Abdominal discomfort
Less common
  • Dizziness
  • Breast tenderness or enlargement, and milk secretion, from raised prolactin
  • Menstrual irregularity
  • Skin rash
Stop and get medical help if any of these occur
  • Palpitations, fainting or an irregular heartbeat
  • Muscle stiffness, tremor, restlessness or involuntary movements
  • Black or tarry stools, or vomiting of blood
  • Difficulty swallowing, unexplained weight loss or persistent vomiting
  • Confusion or hallucinations
03

Precautions

  • Domperidone prolongs the QT interval and has been associated with serious arrhythmia and sudden cardiac death. Contraindicated in known QT prolongation, electrolyte disturbance and underlying cardiac disease; use at the lowest effective dose for no more than about a week.
  • Contraindicated alongside other QT-prolonging drugs and strong CYP3A4 inhibitors including ketoconazole, erythromycin and clarithromycin.
  • Contraindicated in gastrointestinal haemorrhage, mechanical obstruction or perforation, and in prolactin-releasing pituitary tumour.
  • Ranitidine has been withdrawn or restricted in several countries following NDMA detection; be aware of the current regulatory position.
  • Alarm features — weight loss, difficulty swallowing, vomiting blood, black stools, anaemia — need investigation before starting acid suppression.
  • Dose reduction is required in renal impairment for both components.
  • Take before meals for the prokinetic effect, and use in pregnancy and breastfeeding only on medical advice.